Table 2. . Patient’s surgical procedure and distal or locoregional metastatic sites.
| Patients for analysis (n) | Study (year) | Surgical procedure | Treatment regimen | Metastatic at presentation | Ref. |
|---|---|---|---|---|---|
| 1 | Kouvaras et al. (2019) | Partial distal gastrectomy | Pembrolizumab followed by ipralimumab | Pulmonary | [7] |
| 2 | Jelincic et al. (2005) | Partial gastrectomy with splenectomy | Interferon | Nil | [8] |
| 3 | Holmes et al. (2017) | Subtotal gastrectomy, appendectomy and splenectomy | Chemo/radiation‡ | Regional lymph node and appendix | [9] |
| 4 | Zhou et al. (2016) | Total gastrectomy | Oral immunotherapeutic | Nil | [10] |
| 5 | Bahat et al. (2010) | Total gastrectomy | Dacarbazine | Local node | [11] |
| 6 | Bolzacchini et al. (2016) | Surgery† | Pembrolizumab | Nil | [12] |
| 7 | Laskaratos et al. (2014) | Distal gastrectomy | Nil | Nil | [13] |
| 8 | Fotoohi et al. (2019) | Distal esophagectomy and proximal gastrectomy | Refused by patient | Local | [14] |
| 9 | Houissa et al. (2010) | Extended total gastrectomy with splenectomy | Nil | Nil | [15] |
| 10 | Lufrano et al. (2007) | Gastrectomy | Nil | Nil | [16] |
| 11 | Yang et al. (2008) | Esophagogastrectomy, lymphadenectomy, distal pancreatectomy, splenectomy and transverse colectomy | Nil | Regional lymphadenopathy | [17] |
| 12 | Noraidah et al. (2003) | Open sleeve gastrectomy | Nil | Nil | [18] |
| 13 | Loh et al. (2012) | Partial gastrectomy | Nil | Bladder | [19] |
| 14 | Khaliq et al. (2012) | Partial gastrectomy | Nil | Nil | [20] |
| 15 | Kim et al. (2013) | Partial gastrectomy | Nil | Nil | [21] |
| 16 | Konikoff et al. (2019) | Proximal gastrectomy, splenectomy and limited small bowel resection with end-to-end anastomosi | Did not attend for follow-up | Multiple metastatic nodules were also seen in the ileum, root of the mesentery, para-iliac nodes, para-aortic nodes and the liver | [22] |
| 17 | Wang et al. (2016) | Proximal stomach resection | Nil | Brain, liver | [23] |
| 18 | Alazmi et al. (2003) | Resection of the stomach, spleen and greater omentum and D2 lymphadenectomy with additional excision of the lymph nodes of the liver cavity | Nil | Nil | [24] |
| 19 | Cho et al. (2014) | Subtotal gastrectomy with lymph node dissection | Nil | Nil | [25] |
| 20 | Yamamura et al. (2012) | Subtotal gastrectomy with splenectomy | Refused by patient | Nil | [26] |
| 21 | Dabrowski et al. (2015) | Total gastrectomy | Nil | Nil | [27] |
| 22 | Wang et al. (2019) | Total gastrectomy | Nil | Nil | [28] |
| 23 | Callaghan et al. (2018) | Total gastrectomy and lymphadenectomy | Nil | Local nodes | [29] |
| 24 | Lim et al. (2018) | Palliative jejunostomy | Nil | Nil | [30] |
| 25 | Castro et al. (2008) | Nil | Dacarbazine/cisplatin | Regional and axillary lymph nodes | [31] |
| 26 | Wiewiora et al. (2019) | Nil | Chemotherapy‡ | Lung, pancreas | [32] |
| 27 | Augustyn et al. (2015) | Nil | Vemurafenib followed by ipilimumab | Liver and regional lymph nodes | [33] |
| 28 | Lagoudianakis et al. (2006) | Nil | Chemotherapy‡ | Liver | [34] |
| 30 | Phillips et al. (2018) | Nil | Radiotherapy‡ | Nil | [41] |
| 31 | Eshtiaghpour et al. (2014) | Nil | Nil | Liver | [36] |
| 32 | Liang et al. (1995) | Nil | Nil | Liver | [37] |
| 33 | Slater et al. (2014) | Nil | Nil | Brain | [38] |
†
Exact surgical procedure not published in the article.
‡
Treatment regimen not published in the article.